세계의 디지털 치료제(DTx) 시장 : 예측 - 제품별, 수익 모델별, 판매 채널별, 전개 모드별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $10.3 billion in 2025 and is expected to reach $49.9 billion by 2032 growing at a CAGR of 25.2% during the forecast period. Digital Therapeutics (DTx) is evidence-based, clinically evaluated software programs designed to treat, manage, or prevent medical disorders and diseases. They deliver therapeutic interventions directly to patients using devices like smartphones or tablets, often supplementing traditional treatments. Unlike general wellness apps, DTx undergo rigorous clinical trials and regulatory review to ensure safety and efficacy. They can address a wide range of conditions, from diabetes and insomnia to anxiety and ADHD. By combining personalized feedback, data tracking, and behavioral science, DTx empower individuals to take control of their health and improve clinical outcomes-all without relying solely on medication or in-person care.

According to World Health Organization (WHO), in 2019, over one billion people with hypertension (82% of all people with hypertension worldwide) lived in low and middle-income countries.

Market Dynamics:

Driver:

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions is significantly propelling the Digital Therapeutics (DTx) market. As the global burden of these long-term conditions increases, there is growing demand for scalable, personalized, and cost-effective care solutions. DTx platforms offer continuous monitoring, behavior modification, and improved patient engagement, enhancing treatment outcomes. This shift toward proactive and remote disease management is driving adoption across healthcare systems, making DTx an essential component in modern chronic care models.

Restraint:

Data Privacy & Cybersecurity Concerns

Concerns over data privacy and cybersecurity are hampering the growth of the Digital Therapeutics (DTx) market. As DTx platforms handle sensitive health information, vulnerabilities to data breaches and unauthorized access raise serious trust and compliance issues. These risks deter patient adoption and slow provider integration. Stricter regulations like HIPAA and GDPR also increase the complexity and cost of development, making secure, scalable deployment a persistent challenge for DTx companies worldwide.

Opportunity:

Shift toward Preventive Healthcare

The global shift toward preventive healthcare is fueling robust growth in the Digital Therapeutics (DTx) market. As healthcare systems prioritize early intervention and wellness over reactive treatment, DTx solutions offer personalized programs for lifestyle management, risk reduction, and long-term disease prevention. These tools empower patients to take control of their health through real-time feedback, behavior coaching, and digital engagement. This paradigm shift is increasing demand for DTx platforms, positioning them as integral to modern, and cost-effective preventive care strategies worldwide.

Threat:

High Development & Maintenance Costs

High development and maintenance costs pose a significant barrier to the growth of the Digital Therapeutics (DTx) market. Creating clinically validated, regulatory-compliant DTx solutions requires substantial investment in research, design, and ongoing updates. Smaller companies often struggle with resource constraints, limiting innovation and market entry. Additionally, the need for continuous technical support and platform security increases operational expenses, making scalability and widespread adoption more challenging in cost-sensitive healthcare environments.

Covid-19 Impact

The COVID-19 pandemic accelerated the adoption of Digital Therapeutics (DTx) as lockdowns and social distancing highlighted the need for remote healthcare solutions. With in-person visits limited, patients and providers turned to digital platforms for chronic disease management, mental health support, and preventive care. This surge in telehealth acceptance boosted awareness and integration of DTx, solidifying its role as a resilient, scalable solution in post-pandemic healthcare ecosystems.

The smoking cessation segment is expected to be the largest during the forecast period

The smoking cessation segment is expected to account for the largest market share during the forecast period, due to rising awareness of smoking-related health risks. DTx platforms offer evidence-based, scalable interventions-like cognitive behavioral therapy, digital coaching, and personalized tracking-to help individuals quit smoking effectively. These tech-enabled approaches provide accessible, non-invasive support that enhances success rates and long-term abstinence. As public and clinical demand for smoking cessation tools grows, DTx solutions are gaining prominence as vital components in behavioral health management.

The diabetes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diabetes segment is predicted to witness the highest growth rate, due to increasing global prevalence of Type 1 and Type 2 diabetes. DTx solutions offer effective self-management tools, including glucose monitoring, dietary guidance, and digital coaching, empowering patients to better control their condition. These personalized, data-driven interventions enhance adherence and improve clinical outcomes. As healthcare systems seek cost-efficient chronic care solutions, the demand for digital diabetes management is steadily fueling expansion across the DTx landscape.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rapid digital transformation, rising chronic disease prevalence, and increasing smartphone penetration. Governments and healthcare providers are embracing DTx to enhance remote care access and reduce system burdens. With tech-savvy populations and expanding healthcare infrastructure, countries like India, China, and Japan are leading adoption. This favorable environment is driving innovation and investment, positioning Asia Pacific as a dynamic hub for next-generation, patient-centered digital healthcare solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure, high digital literacy, and favorable regulatory support. The region's proactive adoption of tech-enabled healthcare, especially in managing chronic conditions, positions DTx as a cornerstone of modern medical care. Strategic investments, insurance coverage expansion, and strong clinical validation further boost market momentum. With increasing demand for personalized and remote care solutions, North America continues to lead innovation and integration of DTx across diverse therapeutic areas.

Key players in the market

Some of the key players profiled in the Digital Therapeutics (DTx) Market include Pear Therapeutics, Inc., Omada Health, Inc., Livongo Health, Inc., Propeller Health, Akili Interactive Labs, Inc., Better Therapeutics, Inc., Voluntis, Inc., Kaia Health, Happify Health, WellDoc, Inc., Cognoa, Inc., Click Therapeutics, Inc., Big Health, Canary Health, Biofourmis, Lark Health, 2Morrow, Inc., DarioHealth Corp., MindMaze and SilverCloud Health.

Key Developments:

In June 2022, Happify Health, in collaboration with Almirall, launched Claro, a digital wellness program for individuals living with psoriasis in the UK, Spain, and Italy. Designed to tackle the common mental health challenges associated with the condition affecting 20-30% of moderate-to-severe patients-Claro integrates cognitive behavioral therapy, positive psychology, and mindfulness to boost emotional resilience and quality of life.

In August 2021, Happify Health and Higi have joined forces to deliver AI-powered, digitally personalized healthcare through Higi's expansive network of over 10,000 Smart Health Stations located in US retail outlets, including pharmacies and grocery stores.

Products Covered:

• Software & Services
• Devices

Revenue Modals Covered:

• Subscription
• One time Purchase/Licensing
• Outcome/Value based

Sales Channels Covered:

• Business-to-Business (B2B)
• Business-to-Consumer (B2C)

Deployment Modes Covered:

• On-Premises
• Cloud-Based

Applications Covered:

• Diabetes
• Obesity
• Cardiovascular Diseases
• Respiratory Diseases
• Central Nervous System (CNS) Disorders
• Smoking Cessation
• Gastrointestinal Disorders
• Other Applications

End Users Covered:

• Patients
• Providers
• Payers
• Employers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Therapeutics (DTx) Market, By Product

• 5.1 Introduction
• 5.2 Software & Services
• 5.3 Devices

6 Global Digital Therapeutics (DTx) Market, By Revenue Modal

• 6.1 Introduction
• 6.2 Subscription
• 6.3 One time Purchase/Licensing
• 6.4 Outcome/Value based

7 Global Digital Therapeutics (DTx) Market, By Sales Channel

• 7.1 Introduction
• 7.2 Business-to-Business (B2B)
• 7.3 Business-to-Consumer (B2C)

8 Global Digital Therapeutics (DTx) Market, By Deployment Mode

• 8.1 Introduction
• 8.2 On-Premises
• 8.3 Cloud-Based

9 Global Digital Therapeutics (DTx) Market, By Application

• 9.1 Introduction
• 9.2 Diabetes
• 9.3 Obesity
• 9.4 Cardiovascular Diseases
• 9.5 Respiratory Diseases
• 9.6 Central Nervous System (CNS) Disorders
• 9.7 Smoking Cessation
• 9.8 Gastrointestinal Disorders
• 9.9 Other Applications

10 Global Digital Therapeutics (DTx) Market, By End User

• 10.1 Introduction
• 10.2 Patients
• 10.3 Providers
• 10.4 Payers
• 10.5 Employers
• 10.6 Other End Users

11 Global Digital Therapeutics (DTx) Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Pear Therapeutics, Inc.
• 13.2 Omada Health, Inc.
• 13.3 Livongo Health, Inc.
• 13.4 Propeller Health
• 13.5 Akili Interactive Labs, Inc.
• 13.6 Better Therapeutics, Inc.
• 13.7 Voluntis, Inc.
• 13.8 Kaia Health
• 13.9 Happify Health
• 13.10 WellDoc, Inc.
• 13.11 Cognoa, Inc.
• 13.12 Click Therapeutics, Inc.
• 13.13 Big Health
• 13.14 Canary Health
• 13.15 Biofourmis
• 13.16 Lark Health
• 13.17 2Morrow, Inc.
• 13.18 DarioHealth Corp.
• 13.19 MindMaze
• 13.20 SilverCloud Health